Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SV7D
|
|||
| Former ID |
DNC004308
|
|||
| Drug Name |
LOTRAFIBAN
|
|||
| Synonyms |
Lotrafiban; SB 214857; UNII-KLQ306I83X; 171049-14-2; SB-214857; CHEMBL356301; KLQ306I83X; DSSTox_CID_31391; R-Lotrafiban; Lotrafiban [INN]; AC1L2Z4G; DSSTox_RID_97278; DSSTox_RID_97279; DSSTox_GSID_57602; DSSTox_GSID_57603; SCHEMBL29596; CAS-NOCAS_57603; DTXSID7057602; ZINC3812598; Tox21_113990; Tox21_113989; BDBM50054825; SB-214857A; NCGC00319023-02; NCGC00319023-01; (2S)-7-((4,4'-Bipiperidin)-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid; KB-80491; SB-214134; CAS-171049-14-2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Discontinued in Phase 3 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H32N4O4
|
|||
| Canonical SMILES |
CN1CC2=C(C=CC(=C2)C(=O)N3CCC(CC3)C4CCNCC4)NC(C1=O)CC(=O)O
|
|||
| InChI |
1S/C23H32N4O4/c1-26-14-18-12-17(2-3-19(18)25-20(23(26)31)13-21(28)29)22(30)27-10-6-16(7-11-27)15-4-8-24-9-5-15/h2-3,12,15-16,20,24-25H,4-11,13-14H2,1H3,(H,28,29)/t20-/m0/s1
|
|||
| InChIKey |
PYZOVVQJTLOHDG-FQEVSTJZSA-N
|
|||
| CAS Number |
CAS 171049-14-2
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004570) | |||
| REF 2 | Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.Expert Opin Investig Drugs.2000 Nov;9(11):2673-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.